AxoGen (AXGN) Earning Somewhat Favorable News Coverage, Study Shows
Media headlines about AxoGen (NASDAQ:AXGN) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. AxoGen earned a daily sentiment score of 0.10 on Accern’s scale. Accern also gave media coverage about the medical equipment provider an impact score of 46.1445097541129 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Hot Stocks For Today: AxoGen, Inc. (AXGN), Chesapeake Energy Corporation (CHK) – ExpressNewsline (expressnewsline.com)
- Financial Analysis: Integer Holdings Corporation (ITGR) versus AxoGen (AXGN) (americanbankingnews.com)
- AxoGen, Inc. (Nasdaq: AXGN) to Ring The Nasdaq Stock Market Opening Bell – GlobeNewswire (press release) (globenewswire.com)
- AxoGen, Inc. (AXGN) PT Raised to $27 at Wedbush Following … – StreetInsider.com (streetinsider.com)
- AxoGen, Inc. (AXGN) PT Raised to $27 at JMP Securities Following Analyst Day – StreetInsider.com (streetinsider.com)
AXGN has been the topic of several recent research reports. BidaskClub downgraded AxoGen from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Roth Capital reaffirmed a “buy” rating and issued a $21.00 price objective (up previously from $18.00) on shares of AxoGen in a research note on Tuesday, September 12th. Leerink Swann initiated coverage on AxoGen in a research note on Monday, July 31st. They issued an “outperform” rating and a $22.00 price objective on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $18.00 price objective on shares of AxoGen in a research note on Monday, August 21st. Finally, Lake Street Capital raised their price objective on AxoGen from $22.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $24.40.
Shares of AxoGen (NASDAQ:AXGN) opened at $25.70 on Thursday. AxoGen has a 12 month low of $8.05 and a 12 month high of $26.45. The company has a debt-to-equity ratio of 1.93, a current ratio of 3.55 and a quick ratio of 2.95.
AxoGen (NASDAQ:AXGN) last issued its earnings results on Wednesday, November 1st. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). The company had revenue of $16.05 million for the quarter, compared to the consensus estimate of $15.55 million. AxoGen had a negative return on equity of 91.00% and a negative net margin of 24.74%. The business’s revenue for the quarter was up 43.2% compared to the same quarter last year. research analysts anticipate that AxoGen will post -0.33 earnings per share for the current year.
In other AxoGen news, Director Guido J. Neels sold 1,150,000 shares of AxoGen stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $19.74, for a total value of $22,701,000.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Robert James Rudelius sold 16,143 shares of AxoGen stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $18.00, for a total value of $290,574.00. Following the completion of the sale, the director now directly owns 43,273 shares in the company, valued at approximately $778,914. The disclosure for this sale can be found here. 9.33% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/axogen-axgn-earning-somewhat-favorable-news-coverage-study-shows/1720841.html.
AxoGen Company Profile
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.